AAP
STOK icon

Arax Advisory Partners’s Stoke Therapeutics STOK Stock Holding History

Arax Advisory Partners’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.2K Buy
+373
New +$12K ﹤0.01% 4239
2026
Q1 		– Sell
-21
Closed -$667 – 4298
2025
Q4 		$667 Sell
21
-156
-88% -$4.69K ﹤0.01% 3559
2025
Q3 		$4.16K Buy
+177
New +$3.03K ﹤0.01% 2920
2024
Q3 		– Sell
-173
Closed -$2.34K – 2650
2024
Q2 		$2.34K Buy
+173
New +$2.34K ﹤0.01% 1914

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Arax Advisory Partners's STOK Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Stoke Therapeutics (STOK) in Q2 2026: 373 shares worth $12.2K. The stake represents ﹤0.01% of the portfolio and ranks #4239 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in STOK as recently as Q4 2025.

Arax Advisory Partners first reported a position in STOK in Q2 2024 and has held it in 4 quarters since. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Arax Advisory Partners held 373 shares of Stoke Therapeutics worth $12.2K as of Q2 2026.
  • Stoke Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Stoke Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4239 holding.
  • Arax Advisory Partners first reported a position in Stoke Therapeutics in Q2 2024 and has held it in 4 quarters since.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.